Live
- Gnani’s Gen AI Solutions Revolutionising BFSI
- Trump's WHO threat sparks debate on the efficiency of global health governance
- ICC Champions Trophy 2025 Schedule: India vs Pakistan Match Set for February 23 in Dubai
- Champions Trophy 2025: Full Schedule, Match Dates, Venues, Timings, and Updates
- FRAI Urges Government to Provide Technology Platform for Kirana Stores to Stay Competitive
- Not just Gen Z, millennials too: Redditors discuss the wave of pet parenthood embraced by young Indians
- Innovation can expedite the journey to a Smoke-Free future- in focus at Technovation Abu Dhabi
- Pramod Kumar Voola: Pioneering ethical AI and innovation in healthcare technology
- Rahul Vadisetty: Harnessing AI to revolutionize predictive healthcare
- Interview with Sukumar Bisetty: Driving business transformation with technology
Natco Pharma files ANDA for Bosentan tablets
Drug firm Natco Pharma on Tuesday said it has submitted an abbreviated new drug application (ANDA) with the US health regulator for the generic version of Bosentan 32 mg tablets for oral suspension.
Hyderabad: Drug firm Natco Pharma on Tuesday said it has submitted an abbreviated new drug application (ANDA) with the US health regulator for the generic version of Bosentan 32 mg tablets for oral suspension.
Bosentan 32 mg tablets are sold by Actelion Pharmaceuticals US, Inc under the brand name Tracleer, Natco Pharma said.
The company has filed the ANDA with Para IV certification with the US Food and Drug Administration (USFDA), it added.
"Natco believes that its ANDA is possibly the sole first-to-file based on the filing date. We further believe that our ANDA may be eligible for 180 days of marketing exclusivity at the time of potential launch of the product," the company said.
Tracleer is indicated for treatment of pulmonary arterial hypertension, it added.
